Long-term neurological manifestations of COVID-19: prevalence and predictive factors.
COVID-19
Cognitive impairment
Depression
Fatigue
Hyposmia
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
02
05
2021
accepted:
26
08
2021
pubmed:
16
9
2021
medline:
15
12
2021
entrez:
15
9
2021
Statut:
ppublish
Résumé
Clinical investigations have argued for long-term neurological manifestations in both hospitalised and non-hospitalised COVID-19 patients. It is unclear whether long-term neurological symptoms and features depend on COVID-19 severity. From a sample of 208 consecutive non-neurological patients hospitalised for COVID-19 disease, 165 survivors were re-assessed at 6 months according to a structured standardised clinical protocol. Prevalence and predictors of long-term neurological manifestations were evaluated using multivariate logistic regression analyses. At 6-month follow-up after hospitalisation due to COVID-19 disease, patients displayed a wide array of symptoms; fatigue (34%), memory/attention (31%) and sleep disorders (30%) were the most frequent. At neurological examination, 40% of patients exhibited neurological abnormalities, such as hyposmia (18.0%), cognitive deficits (17.5%), postural tremor (13.8%) and subtle motor/sensory deficits (7.6%). Older age, premorbid comorbidities and severity of COVID-19 were independent predictors of neurological manifestations in logistic regression analyses. Premorbid vulnerability and severity of SARS-CoV-2 infection impact on prevalence and severity of long-term neurological manifestations.
Sections du résumé
BACKGROUND
BACKGROUND
Clinical investigations have argued for long-term neurological manifestations in both hospitalised and non-hospitalised COVID-19 patients. It is unclear whether long-term neurological symptoms and features depend on COVID-19 severity.
METHODS
METHODS
From a sample of 208 consecutive non-neurological patients hospitalised for COVID-19 disease, 165 survivors were re-assessed at 6 months according to a structured standardised clinical protocol. Prevalence and predictors of long-term neurological manifestations were evaluated using multivariate logistic regression analyses.
RESULTS
RESULTS
At 6-month follow-up after hospitalisation due to COVID-19 disease, patients displayed a wide array of symptoms; fatigue (34%), memory/attention (31%) and sleep disorders (30%) were the most frequent. At neurological examination, 40% of patients exhibited neurological abnormalities, such as hyposmia (18.0%), cognitive deficits (17.5%), postural tremor (13.8%) and subtle motor/sensory deficits (7.6%). Older age, premorbid comorbidities and severity of COVID-19 were independent predictors of neurological manifestations in logistic regression analyses.
CONCLUSIONS
CONCLUSIONS
Premorbid vulnerability and severity of SARS-CoV-2 infection impact on prevalence and severity of long-term neurological manifestations.
Identifiants
pubmed: 34523082
doi: 10.1007/s10072-021-05586-4
pii: 10.1007/s10072-021-05586-4
pmc: PMC8439956
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4903-4907Informations de copyright
© 2021. The Author(s).
Références
J Neurol Neurosurg Psychiatry. 2021 Feb;92(2):218-220
pubmed: 33055146
PLoS One. 2020 Nov 9;15(11):e0240784
pubmed: 33166287
Brain. 2020 Oct 1;143(10):3104-3120
pubmed: 32637987
Eur J Neurol. 2020 Sep;27(9):1712-1726
pubmed: 32503088
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Lancet Psychiatry. 2021 Feb;8(2):130-140
pubmed: 33181098
Lancet Psychiatry. 2020 Jun;7(6):547-560
pubmed: 32304649
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
J Crit Care. 2020 Aug;58:29-33
pubmed: 32330817
Lancet. 2020 Apr 4;395(10230):1110-1111
pubmed: 32220279
J Neuroinflammation. 2020 Sep 30;17(1):286
pubmed: 32998763
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33257910
J Rehabil Med. 2020 Apr 15;52(4):jrm00044
pubmed: 32286675
Neurol Sci. 2015 Apr;36(4):585-91
pubmed: 25380622
Neuroscientist. 2021 Jan 3;:1073858420984106
pubmed: 33393420
BMJ. 2020 Aug 11;370:m3026
pubmed: 32784198
Alzheimers Res Ther. 2020 Dec 30;12(1):170
pubmed: 33380345
J Am Geriatr Soc. 1968 May;16(5):622-6
pubmed: 5646906
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet Neurol. 2020 Nov;19(11):919-929
pubmed: 33031735
J Gen Intern Med. 1997 Jul;12(7):423-30
pubmed: 9229281